The united states thoracic catheter market size is expected to increase from USD 153.87 million in 2025 to USD 159.78 million in 2026 and reach USD 196.46 million by 2031, growing at a CAGR of 4.22% over 2026-2031. This report is Segmented by Product Type (Thoracostomy Tubes, Pleural Drainage Catheters, and More), Application (Pleural Effusion, and More), Procedure/Access Technique (Seldinger, Surgical, Trocar, Tunneled), Monitoring Modality (Conventional Analog, Digital Drainage), and End User (Hospitals, Ascs, Specialty Clinics, Homecare). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Thoracostomy tubes remain important in trauma, empyema, and postoperative care, but the direction of change is becoming clearer as smaller-bore options gain support in indications where pain reduction and mobility matter. The United States thoracic catheter market is seeing gradual substitution in selected settings because smaller catheters can deliver acceptable outcomes while reducing discomfort and simplifying removal after use. Trocar catheters are the fastest-growing product type, with a 5.46% CAGR through 2031, supported by emergency use cases where placement speed remains a practical advantage. Bundled procedure kits also matter in this segment because they reduce stock complexity for hospitals and help suppliers defend contract positions through convenience as well as price. Product development still moves carefully, since material changes such as movement from PVC to polyurethane or silicone can trigger new qualification work that slows mid-tier innovation cycles under device compliance standards.
Pleural effusion accounted for 36.83% of the US thoracic catheter market size in 2025, which kept it as the largest application category in the country. The size of this segment is tied closely to malignant pleural effusion volume, and that burden remains high with around 150,000 diagnoses each year in the United States. Within pleural effusion care, malignant and non-malignant cases follow different purchasing logic because malignant disease leans more heavily toward indwelling systems and home drainage accessories, while non-malignant fluid often still involves repeat aspiration or shorter-term catheter use. This makes application growth in the US thoracic catheter market more uneven than the headline number suggests, since some sub-indications support premium systems while others continue to favor standard products. The approval history of major tunneled systems has also widened addressable use over time by extending relevance beyond oncology into selected recurrent non-malignant effusion settings.
Pneumothorax is the fastest-growing application segment with a 5.27% CAGR through 2031, and guideline changes are a major reason for that faster rise. The 2024 joint guidance from the European Respiratory Society, the European Association for Cardio-Thoracic Surgery, and the European Society of Thoracic Surgeons supports less invasive approaches for initial primary spontaneous pneumothorax management and conditionally supports ambulatory care in suitable patients PUBMED. That shift is important because it favors small-bore catheter use over older large-bore insertion patterns in part of the treatment pathway. Hemothorax and postoperative drainage still provide a dependable base of demand because they are tied more to trauma and surgical procedure volume than to epidemiology. Empyema remains smaller in value terms, but it keeps large-bore drainage relevant in the US thoracic catheter market because infected or complex pleural collections often require a more aggressive management approach.
United States Thoracic Catheter Market Trends and Insights
Rising Malignant and Recurrent Pleural Effusion Burden
Pleural effusion demand remains central to the US thoracic catheter market because malignant pleural effusion continues to create a large and recurring treatment need. Around 150,000 patients receive a malignant pleural effusion diagnosis each year in the United States, which keeps demand high for both inpatient drainage and longer-term outpatient management approaches. The case burden is also being reinforced by longer survival in cancer care, since patients are living longer with disease and therefore spend a longer period needing symptom control and repeat pleural management. Evidence from pleural care databases has also shown a rise in new malignant pleural effusion diagnoses over time, which supports the same direction of demand pressure described in the US thoracic catheter market. This longer care window increases catheter use per patient because repeat drainage episodes become more likely before pleurodesis or catheter removal can be achieved. As a result, recurrent effusion care is becoming one of the clearest volume drivers for tunneled pleural systems and related accessories in the US thoracic catheter market.First-Line Guideline Acceptance of Indwelling Pleural Catheters
Guideline acceptance has become a direct growth lever for the US thoracic catheter market because indwelling pleural catheters are no longer treated only as a late fallback option. Guidance from the American Thoracic Society, the British Thoracic Society, and the European Respiratory Society now places indwelling pleural catheters alongside other frontline options for recurrent malignant pleural effusion management. In patients with non-expandable lung, the treatment preference is even clearer because guideline recommendations favor indwelling pleural catheters over talc pleurodesis in this setting. The current care gap also matters because only 24% of eligible United States patients receive guideline-consistent definitive management, which leaves a sizable conversion opportunity for programs that expand pleural intervention access. Clinical experience also supports the model, since one prospective cohort reported spontaneous pleurodesis in 44% of indwelling pleural catheter patients, with higher pleural fluid pH and protein associated with success. That combination of stronger guideline backing and underuse in practice gives the United States thoracic catheter market room to grow without depending entirely on new indications.Budget Pressure and GPO-Led Commoditization
Budget pressure remains a real brake on the United States thoracic catheter market because hospitals continue to buy large volumes of standard drainage products through contracts that reward scale and low unit cost. This matters most for conventional thoracostomy tubes and basic drainage kits, where product differentiation is limited, and procurement teams focus heavily on price consistency across large systems. The effect is a split market where standard products face ongoing price compression, while digitally integrated systems and specialized indwelling pleural catheter platforms have a better chance of defending premium pricing if clinical value is clear. That gap slows adoption because hospital committees often want stronger operational and clinical justification before they add new systems to approved purchasing lists. It also changes supplier behavior, since manufacturers are pushed to package products into procedure-specific kits and monitoring platforms rather than compete only on the base catheter itself. The result is that the United States thoracic catheter market keeps growing, but innovation reaches price-sensitive providers more slowly than it reaches advanced thoracic centers.Other drivers and restraints analyzed in the detailed report include:
- Growth in Thoracic and Cardiothoracic Surgeries
- ERAS-Led Adoption of Digital Drainage Workflows
- Catheter Blockage, Infection, and Dislodgement Risk
Segment Analysis
Pleural drainage catheters held 47.23% of the US thoracic catheter market size in 2025, which made them the largest product group in the product mix. This leadership reflects their role across both recurrent oncologic effusion management and short-duration drainage in urgent and planned hospital care. Tunneled indwelling pleural catheters continue to gain procedural weight as clinical guidance becomes more supportive and outpatient care pathways become more common. Non-tunneled pigtail catheters still hold an important high-volume role because they are widely used for diagnostic drainage, temporary pleural decompression, and selected pneumothorax cases. In the US thoracic catheter industry, this combination gives pleural drainage catheters both a broad volume base and a strong link to premiumization.Thoracostomy tubes remain important in trauma, empyema, and postoperative care, but the direction of change is becoming clearer as smaller-bore options gain support in indications where pain reduction and mobility matter. The United States thoracic catheter market is seeing gradual substitution in selected settings because smaller catheters can deliver acceptable outcomes while reducing discomfort and simplifying removal after use. Trocar catheters are the fastest-growing product type, with a 5.46% CAGR through 2031, supported by emergency use cases where placement speed remains a practical advantage. Bundled procedure kits also matter in this segment because they reduce stock complexity for hospitals and help suppliers defend contract positions through convenience as well as price. Product development still moves carefully, since material changes such as movement from PVC to polyurethane or silicone can trigger new qualification work that slows mid-tier innovation cycles under device compliance standards.
Pleural effusion accounted for 36.83% of the US thoracic catheter market size in 2025, which kept it as the largest application category in the country. The size of this segment is tied closely to malignant pleural effusion volume, and that burden remains high with around 150,000 diagnoses each year in the United States. Within pleural effusion care, malignant and non-malignant cases follow different purchasing logic because malignant disease leans more heavily toward indwelling systems and home drainage accessories, while non-malignant fluid often still involves repeat aspiration or shorter-term catheter use. This makes application growth in the US thoracic catheter market more uneven than the headline number suggests, since some sub-indications support premium systems while others continue to favor standard products. The approval history of major tunneled systems has also widened addressable use over time by extending relevance beyond oncology into selected recurrent non-malignant effusion settings.
Pneumothorax is the fastest-growing application segment with a 5.27% CAGR through 2031, and guideline changes are a major reason for that faster rise. The 2024 joint guidance from the European Respiratory Society, the European Association for Cardio-Thoracic Surgery, and the European Society of Thoracic Surgeons supports less invasive approaches for initial primary spontaneous pneumothorax management and conditionally supports ambulatory care in suitable patients PUBMED. That shift is important because it favors small-bore catheter use over older large-bore insertion patterns in part of the treatment pathway. Hemothorax and postoperative drainage still provide a dependable base of demand because they are tied more to trauma and surgical procedure volume than to epidemiology. Empyema remains smaller in value terms, but it keeps large-bore drainage relevant in the US thoracic catheter market because infected or complex pleural collections often require a more aggressive management approach.
Complete Report Scope:
- By Product Type
- Thoracostomy Tubes
- Pleural Drainage Catheters
- Tunneled Indwelling Pleural Catheters
- Non-tunneled Pigtail Pleural Catheters
- Trocar Catheters
- Thoracostomy Procedure Kits and Trays
- By Application
- Pleural Effusion
- Malignant Pleural Effusion
- Non-malignant Pleural Effusion
- Pneumothorax
- Spontaneous Pneumothorax
- Iatrogenic Pneumothorax
- Traumatic Pneumothorax
- Hemothorax
- Postoperative Chest Drainage
- Thoracic Surgery
- Cardiac Surgery
- Empyema and Complicated Pleural Infection
- Pleural Effusion
- By Procedure / Access Technique
- Seldinger-guided Small-bore Placement
- Surgical Thoracostomy Placement
- Trocar-assisted Placement
- Tunneled Indwelling Placement
- By Monitoring Modality
- Conventional Analog and Water-seal Drainage
- Digital Drainage-compatible Solutions
- By End User
- Hospitals
- Academic Medical Centers
- Community Hospitals
- Trauma Centers
- Ambulatory Surgical Centers
- Specialty Clinics
- Interventional Pulmonology Clinics
- Oncology and Palliative Care Clinics
- Homecare Settings
- Hospitals
List of Companies Covered in this Report:
- AngioDynamics
- Argon Medical Devices
- B. Braun
- Beckton Dickinson
- Cardinal Health
- Centese, Inc.
- Cook Group
- Getinge
- ICU Medical
- Medela
- Mediplus Ltd.
- Medtronic
- Merit Medical Systems
- Polymedicure Limited
- Redax S.p.A.
- Rocket Medical plc
- Smiths Group
- Teleflex
- Utah Medical Products
- Vygon
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AngioDynamics, Inc.
- Argon Medical Devices, Inc.
- B. Braun Melsungen AG
- Becton, Dickinson and Company
- Cardinal Health, Inc.
- Centese, Inc.
- Cook Medical
- Getinge AB
- ICU Medical, Inc.
- Medela AG
- Mediplus Ltd.
- Medtronic plc
- Merit Medical Systems, Inc.
- Polymedicure Limited
- Redax S.p.A.
- Rocket Medical plc
- Smiths Medical
- Teleflex Incorporated
- Utah Medical Products, Inc.
- Vygon SA
